Literature DB >> 25704291

Providing information about late effects after childhood cancer: lymphoma survivors' preferences for what, how and when.

Hanne C Lie1, Jon H Loge2, Sophie D Fosså3, Hanne M Hamre3, Siri L Hess3, Anneli V Mellblom4, Ellen Ruud5, Arnstein Finset4.   

Abstract

OBJECTIVE: Childhood cancer survivors need information about risks of late effects to manage their health. We studied how and when adult, long-term survivors prefer to receive information about late effects.
METHODS: Five focus-groups with adult survivors of childhood lymphomas who had completed routine follow-up care and participated in a preceding follow-up study (n = 34, 19 females, mean age = 39). We used thematic analysis to identify themes regarding providing late effects information.
RESULTS: The survivors wanted information about late effects (symptoms, prevention and treatment), lifestyle and social security rights. Information should be tailored, carefully timed, given "face-to-face" and in written format. Many expressed ambivalence regarding receiving information as adolescents, but it was seen as essential "to know" once a late effect occurred. A "re-information" consultation about late effects around age 25 was suggested as beneficial.
CONCLUSION: Although ambivalent, all survivors wanted information about late effects. They preferred individualized information, disclosed "step-by-step" and in a "re-information consultation" when reaching young adulthood. PRACTICE IMPLICATIONS: Providing information about late effects should be an on-going process across the cancer care trajectory. (Re-)Informing survivors when older would enhance their understanding of their health risks and could aid better health self-management beyond completion of follow-up care.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Childhood cancer survivors; Late effects; Patient education; Patient-perspective; Providing information

Mesh:

Substances:

Year:  2015        PMID: 25704291     DOI: 10.1016/j.pec.2015.01.016

Source DB:  PubMed          Journal:  Patient Educ Couns        ISSN: 0738-3991


  6 in total

Review 1.  Evidence-based recommendations for the organization of long-term follow-up care for childhood and adolescent cancer survivors: a report from the PanCareSurFup Guidelines Working Group.

Authors:  Gisela Michel; Renée L Mulder; Helena J H van der Pal; Roderick Skinner; Edit Bárdi; Morven C Brown; Janine Vetsch; Eva Frey; Rachael Windsor; Leontien C M Kremer; Gill Levitt
Journal:  J Cancer Surviv       Date:  2019-08-08       Impact factor: 4.442

2.  Patterns of unmet needs in adolescent and young adult (AYA) cancer survivors: in their own words.

Authors:  Alex W K Wong; Ting-Ting Chang; Katrina Christopher; Stephen C L Lau; Lynda K Beaupin; Brad Love; Kim L Lipsey; Michael Feuerstein
Journal:  J Cancer Surviv       Date:  2017-03-29       Impact factor: 4.442

3.  Providing Information About Late Effects During Routine Follow-Up Consultations Between Pediatric Oncologists and Adolescent Survivors: A Video-Based, Observational Study.

Authors:  Anneli V Mellblom; Live Korsvold; Arnstein Finset; Jon Loge; Ellen Ruud; Hanne C Lie
Journal:  J Adolesc Young Adult Oncol       Date:  2015-12       Impact factor: 2.223

4.  Experiences with late effects-related care and preferences for long-term follow-up care among adult survivors of childhood lymphoma.

Authors:  Hanne C Lie; Anneli V Mellblom; Mette Brekke; Arnstein Finset; Sophie D Fosså; Cecilie E Kiserud; Ellen Ruud; Jon H Loge
Journal:  Support Care Cancer       Date:  2017-02-24       Impact factor: 3.603

5.  Rural cancer survivors' health information needs post-treatment.

Authors:  Nynikka R Palmer; Nancy E Avis; Nora F Fino; Janet A Tooze; Kathryn E Weaver
Journal:  Patient Educ Couns       Date:  2020-02-27

6.  Parent perspectives on information about late effects of childhood cancer treatment and their role in initial treatment decision making.

Authors:  Katie A Greenzang; Angela Dauti; Jennifer W Mack
Journal:  Pediatr Blood Cancer       Date:  2018-01-30       Impact factor: 3.838

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.